Abstract

Globus Medical is scheduled to release fourth-quarter 2025 results on February 24, 2026 Post Market, and this preview consolidates the latest quarterly performance, consensus forecasts for revenue and earnings, and recent institutional commentary to frame what the market is expecting and which business drivers matter now.

Market Forecast

Consensus expectations for the current quarter anticipate revenue of 799.12 million, up 24.21% year over year, EBIT of 207.18 million, up 57.68% year over year, and adjusted EPS of 1.15, up 54.19% year over year. Forecasts imply a notable step-up in earnings growth versus sales growth, consistent with operating leverage and mix benefits; margin estimates for the quarter have not been formally provided in the available forecast dataset and are therefore omitted.

The main business is expected to remain anchored by procedure-driven musculoskeletal products, with case volume normalization and stable pricing mix as core supports to revenue trajectory. Enabling technologies (robotics, navigation, and related platforms) remain the most promising growth vector; this segment generated 28.04 million in revenue in the last reported quarter, and while its year-over-year growth rate is not disclosed in the collected dataset, analysts broadly view its demand pipeline favorably due to new system placements and utilization trends.

Last Quarter Review

In the last reported quarter, Globus Medical delivered revenue of 769.05 million, a gross profit margin of 68.00%, GAAP net profit attributable to the parent company of 119.00 million, a net profit margin of 15.47%, and adjusted EPS of 1.18, with revenue up 22.91% year over year and adjusted EPS up 42.17% year over year. Sequentially, net profit moderated by 41.35% quarter over quarter, reflecting normal intra-year variability and investment timing against a strong multi-quarter expansion in revenue and earnings.

Main business highlights show musculoskeletal products at 741.01 million and enabling technologies at 28.04 million, reflecting a sales mix weighted toward core procedure-based revenue while the technology stack continues to build its installed base; segment-specific year-over-year metrics were not disclosed in the collected dataset.

Current Quarter Outlook (with major analytical insights)

Core Musculoskeletal Solutions

The core musculoskeletal franchise should remain the primary revenue driver this quarter, underpinned by consistent procedure activity and continued adoption of the company’s implant systems across spine and related indications. Consensus projects revenue growth of 24.21% year over year for the quarter, and the magnitude of the increase suggests stable utilization at hospitals and ambulatory sites alongside share capture from portfolio breadth. The relationship between projected EPS growth (54.19% year over year) and revenue growth implies operating leverage in the model, where volume-led expansion and efficiency benefits from prior commercial investments can drop through to earnings at an accelerating rate. The last quarter’s gross margin of 68.00% sets a high base; while no formal margin forecast is available in the collected dataset, the mix of recurring disposables and instruments typically supports resilient unit economics. Pricing remains a watch item across the sector, but the company’s recent revenue cadence indicates it has navigated headwinds in a manner that preserves margin integrity, as seen in the net profit margin of 15.47% last quarter. The key to the quarter for this franchise will be the balance between case volume trajectory and any intra-quarter seasonality, which together should frame whether revenue lands closer to or above the 799.12 million consensus.

Enabling Technologies

Enabling technologies—such as surgical robotics, navigation, and imaging—remain a structurally attractive driver because each new system placement can catalyze multi-year recurring revenue streams from disposables, software, services, and upgrades. The last quarter’s enabling technologies revenue of 28.04 million is modest compared with the overall base but represents a strategic pillar that tends to grow faster once installation density increases. This quarter’s earnings setup benefits if capital pipelines that were qualified earlier in the year close on schedule and if utilization on the installed base remains healthy; these dynamics would reinforce the forecasted outperformance of earnings versus sales. Given that EPS growth is guided by consensus to rise 54.19% year over year, any incremental margin contribution from technology-related services and software would help amplify operating leverage. Capital budgeting remains a gating factor in certain hospital systems, which makes the pace of new placements the variable to watch, but the set-up into February 24, 2026 suggests momentum is intact based on how analysts have leaned in with Buy ratings during January 2026. In sum, while segment-level year-over-year figures are not disclosed in the collected dataset, enabling technologies appear poised to contribute positively to mix and to the sustainability of growth into 2026.

Key Stock Price Swing Factors This Quarter

Three elements are likely to dominate the stock’s immediate reaction: delivery versus the 799.12 million revenue consensus, the earnings quality underpinning the 1.15 adjusted EPS forecast, and forward commentary on the cadence of enabling technology placements and utilization. If revenue lands above the 799.12 million mark and EPS meets or exceeds the 1.15 level, the translation of top-line growth into bottom-line results should validate the projected 57.68% year-over-year growth in EBIT and reinforce market confidence in margin durability. Conversely, since last quarter’s net profit margin was 15.47%, any sign of compression—whether due to one-time costs, integration investments, or pricing—could temper the multiple even if revenue is broadly in line. Investors will also parse qualitative disclosures on capital cycles within hospital customers; indications that decision timelines remain predictable would help frame the trajectory for enabling technologies and inform expectations for the next several quarters. On balance, the distributive nature of growth—core musculoskeletal volumes complemented by enabling technology placements—positions the story to leverage scale benefits, and analysts’ recent posture suggests the bar, while higher, is viewed as achievable if execution remains steady.

Analyst Opinions

Bullish views hold the clear majority in recent months, with Buy ratings significantly outnumbering bearish calls from January 1, 2026 through February 17, 2026; across the collected opinions in that period, bullish ratings stand at four, with zero bearish ratings identified, while one neutral stance was observed but excluded from the bullish-versus-bearish ratio. RBC Capital reiterated a Buy rating with a 100.00 target on January 7, 2026, underscoring confidence in continued growth heading into the February 24, 2026 report. Jefferies reiterated a Buy rating with a 115.00 target on January 8, 2026, aligning upside potential with expectations for robust earnings expansion implied by the 54.19% year-over-year EPS growth forecast. Piper Sandler reaffirmed a Buy rating on January 8, 2026, signaling constructive expectations for execution in the near term, while Needham upgraded to Buy with a 112.00 target on January 30, 2026, indicating improving conviction in the company’s trajectory as the quarter progressed.

The majority bullish camp highlights a few points that connect directly to this quarter’s setup. First, the slope of expected earnings growth versus sales growth—EPS up 54.19% year over year on revenue up 24.21%—supports the case for meaningful operating leverage, which tends to sustain valuation support when delivered consistently. Second, the enabling technologies suite is viewed as a multiplier over time, where incremental placements and higher utilization can expand recurring and software-linked revenues in ways that are beneficial to margin mix. Third, the last reported quarter delivered a 68.00% gross margin and a 15.47% net profit margin; while not guaranteeing future results, the quality of these metrics helps justify the view that profit growth can keep pace with or exceed revenue growth if volumes remain strong and pricing stays stable. On this basis, the majority of institutions anticipate a constructive print and guide, particularly if the company can evidence continued discipline on costs while maintaining the momentum seen in the 22.91% year-over-year revenue growth recorded last quarter. The bullish cohort’s perspective is that execution against these markers could catalyze positive estimate revisions and underpin the recent target ranges near 100.00 to 115.00, with upside skew if enabling technology contributions accelerate and if core volumes meet expectations.